Bedside Snapshot
- Recognize
- Dyspnea and/or cough and sputum worsening over days (up to 14), with tachypnea or tachycardia; classify as mild, moderate or severe (Rome)
- Red Flags
- Drowsiness or confusion; accessory muscle use; SpO₂ not rising on controlled oxygen; ABG pH <7.35 with PaCO₂ >45 mmHg (pH ≤7.25 with PaCO₂ >60 mmHg: ventilatory failure)
- First Actions
- Sit upright; controlled oxygen to SpO₂ 88–92%
- Air-driven albuterol nebulizer; add ipratropium early
- Prednisone 40 mg PO daily for 5 days
- Antibiotics only if sputum criteria are met; NIV early for acidosis
- Key Doses
- Albuterol 2.5 mg nebulized as the starting dose, then hourly for 2–3 doses per protocol; ipratropium 0.5 mg with the first doses; prednisone 40 mg PO daily ×5 days
- Don't Miss
- Pneumonia, pulmonary embolism, heart failure, pneumothorax or ACS; oxygen plus sedation hides CO₂ retention
- Escalate & Transport
- NIV for hypercapnic acidosis; intubation after NIV failure; monitored bed or respiratory unit; transport on controlled oxygen with EtCO₂ and continuous ECG
Definition & Pathophysiology
A COPD exacerbation is a flare. Symptoms get worse over a few days (up to 14), beyond their usual day-to-day variation. You see more dyspnea and/or more cough and sputum, and tachypnea or tachycardia may come with them. Why does the work of breathing go up? More airway inflammation, more mucus and more gas trapping all raise it. Ventilation-perfusion mismatch drives the hypoxemia. The dangerous part is CO₂. When fatigue and trapped gas stop it clearing, PaCO₂ climbs and pH falls. That is hypercapnic respiratory failure.
- Triggers: respiratory viruses (rhinovirus, influenza, parainfluenza, metapneumovirus) most often; bacterial infection; air pollution; extreme heat or cold; wildfire smoke
- Course: symptoms usually last 7–10 days; up to 20% have not returned to baseline at 8 weeks
- Outcome: readmission in 30–50% of patients within 30 days of discharge
Recognition & Red Flags
Rome severity classification
- Mild: dyspnea VAS <5; RR <24; HR <95; SpO₂ ≥92% on room air (or usual oxygen); CRP <10 mg/L if available
- Moderate: at least 3 of 5: dyspnea VAS ≥5; RR ≥24; HR ≥95; SpO₂ <92% on room air; CRP ≥10 mg/L
- Severe: the same clinical variables as moderate, with an ABG showing PaO₂ ≤60 mmHg and/or PaCO₂ >45 mmHg with pH <7.35 when one is obtained (GOLD 2026 Figure 4.1)
Red Flags
- Drowsiness, confusion or new agitation. Each one signals ventilatory failure.
- Accessory muscle use, paradoxical breathing or inability to speak in full sentences
- SpO₂ that does not rise on controlled oxygen, or that falls
- Silent chest or markedly reduced air entry
Assessment & Diagnostics
Clinical signs make the diagnosis. Get gas exchange early. Who needs it? Anyone drowsy, hypoxemic on controlled oxygen, or not improving after the first bronchodilator doses.
| Check | Why | Act If |
|---|---|---|
| SpO₂ and RR | Hypoxemia and CO₂ retention | SpO₂ <88% on controlled oxygen, or RR >24 with accessory muscle use: escalate and consider NIV |
| Mental status | Drowsiness is an early sign of ventilatory failure | Drowsy or confused: obtain a blood gas now; use NIV only if the airway is protected and NIV is not contraindicated, otherwise prepare for an advanced airway |
| ABG or VBG (see pH and PaCO₂) | ABG is the reference standard. A venous gas approximates pH and PaCO₂ and should not be used to rule out hypercapnia; confirm with an arterial sample if it is abnormal or concern persists | pH <7.35 with PaCO₂ >45 mmHg: NIV pathway after initial bronchodilator and controlled-oxygen treatment. pH ≤7.25 with PaCO₂ >60 mmHg: ventilatory failure, so plan for ICU-level care and early intubation, as in the GOLD 2026 classification |
| 12-lead ECG | Ischemia and arrhythmia are common co-triggers | Ischemic change or new AF: treat per the ACS or arrhythmia pathway |
| Capnography (EtCO₂) | Trends CO₂ in the field and in transit | Rising EtCO₂ with falling RR or mental status: treat as impending failure |
| Sputum change | Identifies antibiotic criteria | At least two of: more dyspnea, fever, more sputum volume, purulent sputum (if purulence is one of the two); or a prior positive sputum culture during a previous exacerbation; or need for invasive or noninvasive ventilation: antibiotics |
| CRP and chest imaging | CRP is a Rome criterion; imaging excludes pneumonia and pneumothorax | CRP ≥10 mg/L supports moderate or worse; a new consolidation or pneumothorax changes the plan |
Differential & Mimics
- Asthma or asthma-COPD overlap: reversible obstruction and earlier onset. In the field, the bronchodilator and steroid steps are the same
- Heart failure: bilateral crackles, orthopnea, edema and raised JVP. Lack of wheeze does not rule it out
- Pneumonia: fever, focal crackles or consolidation on imaging
- Pulmonary embolism: sudden onset, tachycardia out of proportion, pleuritic pain, hypoxemia without wheeze
- Pneumothorax: unilateral absent breath sounds, tracheal deviation or hypotension
BLS Management
- Scene safety and assessment: check airway, breathing, SpO₂, RR and mental status; sit the patient upright in the tripod position.
- Oxygen: apply controlled oxygen to SpO₂ 88–92% when COPD is suspected. Do not use high-concentration oxygen by default.
- Bronchodilator: assist with the patient's own inhaler or spacer, and report the time and dose to ALS. Scope for EMTs and AEMTs to give nebulized albuterol or ipratropium depends on state and agency protocol.
- Do not sedate: avoid sedatives and opioids. They drive down ventilation.
- Reassess every 5 minutes: SpO₂, RR, mental status and work of breathing; escalate early if drowsiness or accessory muscle use appears.
ALS Management
Doses vary by protocol; follow local protocols and medical direction.
- Bronchodilator (Paramedic/RN/CCT): albuterol nebulized, starting at 2.5 mg, then repeated hourly for 2–3 doses and every 2–4 hr according to response and heart rate (protocol-dependent). The FDA label for the 0.5% solution says 2.5 mg 3 to 4 times daily and that higher doses are not recommended, so repeated 5 mg doses need protocol support. Avoid high-dose SABA. Reassess before every repeat dose. Add ipratropium 0.5 mg to the first 1–3 albuterol doses. Use a well-fitted mask or mouthpiece and keep mist away from the eyes (angle-closure glaucoma risk). Monitor heart rate and rhythm with repeated doses. See Albuterol and Ipratropium.
- Steroid (Paramedic/RN/CCT): prednisone 40 mg PO once daily for 5 days; oral is as effective as IV. If oral is not possible, IV methylprednisolone at the equivalent dose (32 mg daily). In some patients, GOLD 2026 lists nebulized budesonide as an alternative. Save steroid bursts for significant exacerbations only. They are linked to pneumonia, sepsis and hyperglycemia, so check glucose in diabetics. You get more benefit with higher blood eosinophils. The REDUCE trial and GOLD 2026 back the 5-day course. See Prednisone and Methylprednisolone.
- Oxygen: titrate to SpO₂ 88–92%, with EtCO₂ where you have it. In a prehospital RCT, titrated oxygen reduced mortality compared with high-flow oxygen in COPD. See Oxygen.
- Noninvasive ventilation (RN/CCT, per local protocol): start it after initial bronchodilator and controlled-oxygen treatment, once there is acute respiratory acidosis (pH <7.35 with PaCO₂ >45 mmHg) or ventilatory failure. See Noninvasive Ventilation.
- NIV contraindications and reassessment: respiratory arrest or apnea; inability to protect the airway or active vomiting; untreated pneumothorax; facial trauma or a mask that cannot seal; hemodynamic instability. Reassess clinical response and gas at about 1 hour. If the acidosis is worsening, consciousness is falling or they are exhausted, prepare for intubation.
- Prehospital CPAP/BiPAP (Paramedic; AEMT where scope allows; protocol-dependent): consider it for severe dyspnea with accessory muscle use and hypercapnic features, once the same contraindications are excluded and the mask fits. If they fail to improve, their consciousness falls or they vomit, stop and prepare to intubate. See Noninvasive Ventilation.
- Antibiotics: give when at least two of these symptoms apply: more dyspnea, fever, more sputum volume, or purulent sputum (if purulence is one of the two); or a prior positive sputum culture during a previous exacerbation; or need for invasive or noninvasive ventilation. Pick the agent by local resistance patterns: an aminopenicillin with clavulanate, a macrolide, a tetracycline or, selectively, a quinolone. Plan a total course of 5–7 days, and 5 days or less for outpatient treatment.
- Do not use: IV methylxanthines (theophylline or aminophylline) are not recommended because of their side-effect profile. IV magnesium is not part of GOLD 2026 COPD pharmacotherapy, so this pathway does not use it.
ED & ICU Management
- Escalate care: admit to a monitored or respiratory-care bed once they need NIV or high-flow oxygen. Severe exacerbations may need an intermediate or ICU bed.
- High-flow nasal oxygen: an option for hypoxemic patients who cannot tolerate NIV. The 2022 ERS high-flow guideline gives a conditional recommendation to trial NIV before HFNC in COPD with hypercapnic acute respiratory failure. Some RCTs, summarized by GOLD 2026, found HFNT non-inferior to NIV in hypercapnic respiratory failure. In one trial, about 30% of patients switched to NIV. So HFNC is an alternative for NIV-intolerant patients, and NIV stays first line for acidosis.
- NIV: the initial ventilation mode for acute COPD respiratory failure. The 2017 ERS/ATS NIV guideline also covers COPD exacerbation. RCTs report an 80–85% success rate, with lower intubation and mortality. Stop NIV straight away once the patient breathes unassisted for at least 4 hours. No weaning phase is needed.
- Invasive ventilation: indicated after NIV failure or when NIV is contraindicated. Patients who fail NIV face greater morbidity and mortality. The hazards are ventilator-associated pneumonia, barotrauma and tracheostomy. See Mechanical Ventilation and RSI.
- Repeat gas exchange: once NIV starts, repeat the ABG. You want to see pH and PaCO₂ improving.
- Thromboprophylaxis: hospitalized COPD patients carry a raised DVT and PE risk. Prophylaxis is recommended.
- Discharge: keep LABA and LAMA therapy running from the hospital. Consider adding an ICS if there was at least one moderate or severe exacerbation and blood eosinophils are elevated. Arrange follow-up within 1 month.
Transport Considerations
- Destination: the nearest facility able to deliver NIV, ABG testing and respiratory care, per regional plan.
- Oxygen in transit: keep SpO₂ at 88–92% with controlled titration; check mental status and RR at each reassessment. Do not stop oxygen abruptly.
- Intubated COPD patients: use a low rate and long expiratory time, and watch the flow waveform for auto-PEEP (dynamic hyperinflation). Auto-PEEP can drop blood pressure and cause barotrauma. Until proven otherwise, treat unexplained hypotension after intubation or bagging as hyperinflation. Disconnect briefly to relieve the trapped air, and consider pneumothorax. See Ventilator Troubleshooting.
- Monitor: continuous SpO₂, EtCO₂ and ECG; check NIV settings and seal at each reassessment.
- Equipment and drugs: air-driven nebulizer, albuterol and ipratropium, prednisone or IV methylprednisolone, suction, NIV interface and backup airway equipment.
- Handoff: SpO₂ and oxygen flow, EtCO₂ trend, last ABG, bronchodilator and steroid times, antibiotic start time, response to NIV if started.
Special Populations
- Pediatrics: COPD is an adult diagnosis. Wheeze in children is managed on the asthma or bronchiolitis pathways. See Respiratory Distress and Failure. This pathway is not established in children, so use weight-based dosing for any pediatric drug.
- Pregnancy: uncommon in this population. Maternal hypoxemia threatens the fetus. So do not withhold oxygen or bronchodilators. Pick steroid and antibiotic therapy with obstetric and pharmacy input.
- Older Adults: higher risk of heart failure, ischemia, pneumonia and pulmonary embolism. Reassess the cause before you pin dyspnea on COPD alone.
- Obesity: hypoventilation is common. Watch for CO₂ retention on oxygen and during sedation.
- Renal Impairment: no specific adjustment is established for the bronchodilator or steroid doses on this page. For antibiotic dosing, consult pharmacy.
- Patients on Long-Term Oxygen: continue the prescribed home flow during treatment and titrate to the 88–92% target.
Pitfalls & Safety Checks
- Error: pushing high-concentration oxygen to a 94–98% target in a patient with CO₂ retention. Titrate to SpO₂ 88–92% instead.
- Error: mistaking drowsiness for relaxation. Oxygen plus sedation hides hypoventilation. Watch RR and EtCO₂, not just the oximeter.
- Error: an oxygen-driven nebulizer. Drive it with air.
- Error: repeating albuterol without reassessment. High-dose SABA causes tachycardia and arrhythmia. Reassess before each repeat dose.
- Error: ipratropium mist reaching the eyes through a loose mask. Use a well-fitted mask or mouthpiece. Mist can trigger acute angle-closure glaucoma.
- Error: IV aminophylline for refractory bronchospasm. Methylxanthines are not recommended here.
- Error: missing pneumonia, pulmonary embolism, heart failure or pneumothorax when treatment isn't working.
- Error: antibiotics withheld when the criteria are met, or started without them. Apply the symptom, prior-culture and ventilation criteria. Send a sputum culture in frequent exacerbations, severe obstruction or ventilated patients.
- Error: NIV started in a drowsy patient who can't protect the airway, or kept running after they fail to improve. Check contraindications. Reassess at about 1 hour.
Clinical Pearls
References
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2025). Global strategy for the prevention, diagnosis and management of COPD: 2026 report. https://goldcopd.org/wp-content/uploads/2026/01/GOLD-REPORT-2026-v1.3-8Dec2025_WMV2.pdf
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2025). Pocket guide to COPD diagnosis, management and prevention: 2026 report. https://goldcopd.org/wp-content/uploads/2026/01/GOLD-Pocket-Guide-2026-v1.1-20Nov2025_WMV2.pdf
- Lee HJ, Lee JK, Park TY, Heo EY, Kim DK, Lee HW. (2023). Validation of the Rome proposal for severity of acute exacerbation of chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666231172917
- Rochwerg B, Brochard L, Elliott MW, et al. (2017). Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. European Respiratory Journal, 50, 1602426. https://doi.org/10.1183/13993003.02426-2016
- British Thoracic Society. (2017). BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax, 72(Suppl 1), ii1–ii90. https://doi.org/10.1136/thoraxjnl-2016-209729
- Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. (2010). Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ, 341, c5462. https://pmc.ncbi.nlm.nih.gov/articles/PMC2957540/
- Leuppi JD, et al. (2013). Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial (landmark trial). JAMA, 309(21), 2223–2231. https://doi.org/10.1001/jama.2013.5023
- Oczkowski S, Ergan B, Bos L, et al. (2022). ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure. European Respiratory Journal, 59(4), 2101574. https://doi.org/10.1183/13993003.01574-2021
- Marini JJ. (2011). Dynamic hyperinflation and auto-positive end-expiratory pressure: lessons learned over 30 years. American Journal of Respiratory and Critical Care Medicine, 184(7), 756–762. https://doi.org/10.1164/rccm.201102-0226PP
Medical Disclaimer
- For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
- Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
- Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.